6 minutes | Jan 25, 2021

Continuation versus discontinuation of RAAS inhibitors in hospitalized patients with COVID-19

A prospective, randomized, open-label trial performed to evaluate whether continuation of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is beneficial or harmful in patients who are admitted to hospital with COVID-19.
Play
Like
Play Next
Mark
Played
Share